204 related articles for article (PubMed ID: 582795)
21. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent.
Aneja R; Dhiman N; Idnani J; Awasthi A; Arora SK; Chandra R; Joshi HC
Cancer Chemother Pharmacol; 2007 Nov; 60(6):831-9. PubMed ID: 17285314
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery.
Dow J; Dulery BD; Hornsperger JM; Di Francesco GF; Keshary P; Haegele KD
Arzneimittelforschung; 1995 Dec; 45(12):1245-52. PubMed ID: 8595078
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and body distribution of amiodarone in man.
Plomp TA; van Rossum JM; Robles de Medina EO; van Lier T; Maes RA
Arzneimittelforschung; 1984; 34(4):513-20. PubMed ID: 6540111
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of toloxatone in man following intravenous and oral administrations.
Benedetti MS; Rovei V; Dencker SJ; Nagy A; Johansson R
Arzneimittelforschung; 1982; 32(3):276-80. PubMed ID: 7200786
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of azapropazone in the elderly.
Ritch AE; Perera WN; Jones CJ
Br J Clin Pharmacol; 1982 Jul; 14(1):116-9. PubMed ID: 7104163
[TBL] [Abstract][Full Text] [Related]
26. [On the determination of azapropazone from plasma by direct quantitative thin-layer chromatography (author's transl)].
Geissler HE; Mutschler E; Faust-Tinnefeldt G
Arzneimittelforschung; 1977; 27(9):1713-5. PubMed ID: 579143
[TBL] [Abstract][Full Text] [Related]
27. Concentration of azapropazone in synovial tissues and fluid.
Spahn H; Thabe K; Mutschler E; Tillmann K; Gikalov I
Eur J Clin Pharmacol; 1987; 32(3):303-7. PubMed ID: 3595703
[TBL] [Abstract][Full Text] [Related]
28. [Azapropazone plasma levels under simultaneous treatment with an antacid or laxative].
Faust-Tinnefeldt G; Geissler HE; Mutschler E
Arzneimittelforschung; 1977; 27(12):2411-4. PubMed ID: 580058
[TBL] [Abstract][Full Text] [Related]
29. Pipotiazine pharmacokinetics after p.o. and i.v. administration in man. Correlation between blood levels and effect on the handwriting area.
De Schepper PJ; Vranckx C; Verbeeck R; Van den Berghe ML
Arzneimittelforschung; 1979; 29(7):1056-62. PubMed ID: 40577
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of the anti-leishmanian agent WR 6026 in dogs.
Taylor T; Hawkins DR; Morris GR; Chung H
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():136-9. PubMed ID: 1820868
[TBL] [Abstract][Full Text] [Related]
31. [Preliminary pharmacokinetics of metoclopramide in humans. Plasma levels following a single oral and intravenous dose (author's transl)].
Schuppan D; Schmidt I; Heller M
Arzneimittelforschung; 1979; 29(1):151-4. PubMed ID: 582108
[TBL] [Abstract][Full Text] [Related]
32. The pharmacology and pharmacokinetics of azapropazone - a review.
Jones CJ
Curr Med Res Opin; 1976; 4(1):3-16. PubMed ID: 770078
[TBL] [Abstract][Full Text] [Related]
33. Disposition of azapropazone in chronic renal and hepatic failure.
Breuing KH; Gilfrich HJ; Meinertz T; Wiegand UW; Jähnchen E
Eur J Clin Pharmacol; 1981; 20(2):147-55. PubMed ID: 7262176
[No Abstract] [Full Text] [Related]
34. Distribution of azapropazone and its principal 8-hydroxy-metabolite in plasma, urine and gastrointestinal mucosa determined by HPLC.
Rainsford KD
J Pharm Pharmacol; 1985 May; 37(5):341-5. PubMed ID: 2862244
[TBL] [Abstract][Full Text] [Related]
35. Ranitidine: single dose pharmacokinetics and absolute bioavailability in man.
van Hecken AM; Tjandramaga TB; Mullie A; Verbesselt R; de Schepper PJ
Br J Clin Pharmacol; 1982 Aug; 14(2):195-200. PubMed ID: 6125204
[TBL] [Abstract][Full Text] [Related]
36. The determination of azapropazone in blood plasma.
Leach H
Curr Med Res Opin; 1976; 4(1):35-43. PubMed ID: 1261300
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of ketanserin in man.
Reimann IW; Okonkwo PO; Klotz U
Eur J Clin Pharmacol; 1983; 25(1):73-6. PubMed ID: 6617728
[TBL] [Abstract][Full Text] [Related]
38. Absolute oral bioavailability and metabolic turnover of β-sitosterol in healthy subjects.
Duchateau G; Cochrane B; Windebank S; Herudzinska J; Sanghera D; Burian A; Müller M; Zeitlinger M; Lappin G
Drug Metab Dispos; 2012 Oct; 40(10):2026-30. PubMed ID: 22826463
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and pharmacodynamics in man of the dopamine antagonist ergot derivative, bromerguride.
Krause W; Sauerbrey N; Gräf KJ
Eur J Clin Pharmacol; 1986; 31(2):165-8. PubMed ID: 3803415
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of oxmetidine, a new histamine H2-receptor antagonist, after single oral and intravenous doses.
Jönsson KA; Bodemar G; Gotthard R; Norlander B; Walan A
Eur J Clin Pharmacol; 1983; 24(3):353-6. PubMed ID: 6134622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
